We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
Read MoreHide Full Article
Key Takeaways
Sanofi's new and acquired drugs saw sales jump 48.3% to 1.3 billion in Q2.
Altuviiio, Ayvakit and Sarclisa led growth, with Ayvakit expected to become a blockbuster in 2026.
Sanofi expects newer launches to generate about 10 billion in annual sales by 2030.
Sanofi’s (SNY - Free Report) most important medicine remains its immunology drug, Dupixent, which continues to be the company’s primary growth engine. Dupixent sales represented roughly 42% of Sanofi’s first-half 2026 revenues.
Sanofimarkets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
At the same time, Sanofi is seeing a good uptake of its new medicines like novel recombinant factor VIII therapy, Altuviiio, and cancer drugs, Ayvakit and Sarclisa, which are important for broadening the company’s growth base.
Sales of its new and acquired drugs rose 48.3% at constant exchange rates to €1.3 billion in the second quarter, led by Altuviiio, Ayvakit and Sarclisa. Altuviiio achieved blockbuster sales in 2025. Ayvakit, added from the Blueprint Medicines acquisition, is expected to become the next blockbuster drug in 2026. Beyfortus (in partnership with AstraZeneca [AZN]) achieved blockbuster sales in its first full year of sales in 2024 and continues its expansion into new geographies.
Some other new products approved in the past couple of years include Wayrilz (rilzabrutinib), for immune thrombocytopenia, and Qfitlia (fitusiran), to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. Cenrifki (tolebrutinib) was approved for treating non-relapsing secondary progressive multiple sclerosis in the EU in June 2026, while in the United States, Sanofi’s regulatory application seeking approval of tolebrutinib was issued a complete response letter in December 2025. Sanofi’s new drug application seeking approval for venglustat for Gaucher Disease is under FDA’s priority review, with a decision expected in November. Venglustat is also under regulatory review in the EU.
The newer medicines should become an increasingly important contributor to Sanofi’s revenue growth in the coming quarters, even as Dupixent remains the largest driver. Sanofi now expects its Pharma launches to generate approximately €10 billion of annual sales by 2030, compared with about €25 billion for Dupixent. This suggests the company is positioning Altuviiio, Ayvakit, Sarclisa and other newer medicines to gradually broaden its revenue base and reduce reliance on Dupixent over the longer term.
SNY’s Price, Valuation & Estimate Movement
Sanofi stock has plunged 15.5% year to date against an appreciation of 11.7% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 7.82 forward earnings, lower than 18.08 for the industry. The stock is also trading below the stock’s 5-year mean of 11.11. The stock is much cheaper than most large drugmakers like Eli Lilly (LLY - Free Report) , Novo Nordisk, AstraZeneca (AZN - Free Report) , J&J, Merck, AbbVie and others.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $4.96 per share to $5.07 per share over the past 60 days.For 2027, earnings estimates have risen from $5.18 per share to $5.29 per share over the same timeframe.
View the Zacks #1 Rank List
Image: Bigstock
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
Key Takeaways
Sanofi’s (SNY - Free Report) most important medicine remains its immunology drug, Dupixent, which continues to be the company’s primary growth engine. Dupixent sales represented roughly 42% of Sanofi’s first-half 2026 revenues.
Sanofimarkets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
At the same time, Sanofi is seeing a good uptake of its new medicines like novel recombinant factor VIII therapy, Altuviiio, and cancer drugs, Ayvakit and Sarclisa, which are important for broadening the company’s growth base.
Sales of its new and acquired drugs rose 48.3% at constant exchange rates to €1.3 billion in the second quarter, led by Altuviiio, Ayvakit and Sarclisa. Altuviiio achieved blockbuster sales in 2025. Ayvakit, added from the Blueprint Medicines acquisition, is expected to become the next blockbuster drug in 2026. Beyfortus (in partnership with AstraZeneca [AZN]) achieved blockbuster sales in its first full year of sales in 2024 and continues its expansion into new geographies.
Some other new products approved in the past couple of years include Wayrilz (rilzabrutinib), for immune thrombocytopenia, and Qfitlia (fitusiran), to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A and B. Cenrifki (tolebrutinib) was approved for treating non-relapsing secondary progressive multiple sclerosis in the EU in June 2026, while in the United States, Sanofi’s regulatory application seeking approval of tolebrutinib was issued a complete response letter in December 2025. Sanofi’s new drug application seeking approval for venglustat for Gaucher Disease is under FDA’s priority review, with a decision expected in November. Venglustat is also under regulatory review in the EU.
The newer medicines should become an increasingly important contributor to Sanofi’s revenue growth in the coming quarters, even as Dupixent remains the largest driver. Sanofi now expects its Pharma launches to generate approximately €10 billion of annual sales by 2030, compared with about €25 billion for Dupixent. This suggests the company is positioning Altuviiio, Ayvakit, Sarclisa and other newer medicines to gradually broaden its revenue base and reduce reliance on Dupixent over the longer term.
SNY’s Price, Valuation & Estimate Movement
Sanofi stock has plunged 15.5% year to date against an appreciation of 11.7% for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Sanofi appears attractive relative to the industry. Going by the price/earnings ratio, the company’s shares currently trade at 7.82 forward earnings, lower than 18.08 for the industry. The stock is also trading below the stock’s 5-year mean of 11.11. The stock is much cheaper than most large drugmakers like Eli Lilly (LLY - Free Report) , Novo Nordisk, AstraZeneca (AZN - Free Report) , J&J, Merck, AbbVie and others.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings has risen from $4.96 per share to $5.07 per share over the past 60 days.For 2027, earnings estimates have risen from $5.18 per share to $5.29 per share over the same timeframe.
Image Source: Zacks Investment Research
Sanofi has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.